ZHANG Zhan-xin，LOU Xue-ling，YAO Li.. The role of SREBP1 in the oncogenesis and development of cervical cancer.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015060121.
［1］ Jemal A，Bray F，Center MM，et al. Global cancer statistics［J］. CA，2011，61：69-90. ［2］ Fang J，Zhang H，Jin S. Epigenetics and cervical cancer：from pathogenesis to therapy［J］. Tumour Biol，2014， 35（6）：5083-5093.［3］ Deberardinis RJ，Sayed N，Ditsworth D，et al. Brick by brick：metabolism and tumor cell growth［J］. Curr Opin Genet Develop，2008，18（1）：54-61. ［4］ Swinnen JV，Brusselmans K，Verhoeven G. Increased lipogenesis in cancer cells：new players，novel targets［J］. Curr Opin Clin Nutr Metab Care，2006，9（4）：358-365. ［5］ Menendez JA，Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis［J］. Nat Rev Cancer，2007，7（10）：763-777. ［6］ Ren S，Li X，Rodriguez-Agudo D，et al. Sulfated oxysterol，25HC3S，is a potent regulator of lipid metabolism in human hepatocytes［J］. Biochem Biophys Res Commun，2007，360（4）：802-808. ［7］ Li W，Tai Y，Zhou J，et al. Repression of endometrial tumor growth by targeting SREBPl and lipogenesis［J］. Cell Cycle 2012，11（12）：2348-2358. ［8］ Yamashita T，Honda M，Takatori H，et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma［J］. J Hepatol，2009，50（1）：100-110. ［9］ Fimita E，Pai SK，Zhan R，et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1［J］. Cancer Res，2008，68（4）：1003-1011. ［10］ Migita T，Ruiz S，Fornari A，et al. Fatty acid synthase：a metabolic enzyme and candidate oncogene in prostate cancer［J］. J Natl Cancer Inst，2009，101（7）：519-532. ［11］ Jung SY，Jeon HK，Choi JS，et al． Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cell［J］. J Cell Biochem，2012，113（12）：3730-3739．［12］ Vazquez-Martin A，Colomer R，Brunet J，et al. Overexpression of fatty acid synthase gene activates HERl /HER2 tyrosine kinase receptors in human breast epithelial cells［J］. Cell Prolif，2008，41（1）：59-85．［13］ Menendez JA，Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis［J］. Nat Rev Cancer，2007，7（10）：763-777．［14］ Lupu R，Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer：an alternative to selective estrogen receptor modulators?［J］. Endocrinology，2006，147（9）：4056-4066. ［15］ Eberhard Y，Gronda M，Hurren R，et al. Inhibition of SREBP1 sensitizes cells to death ligands［J］. Oncotarget，2011，2（3）：186-196. ［16］ Yamashita T，Honda M，Takatori H，et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma［J］. J Hepatol，2009，50（1）：100-110. ［17］ Li JN，Mahmoud MA，Han WF，et al. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia［J］. Experim Cell Res，2000，261（1）：159-165. ［18］ Rahaman MT，Nakayama K，Ishikawa M，et al. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer［J］. Oncology，2013，84（3）：166-173．［19］ DeAngelis T，Wu K，Pestell R，et al． The type 1 insulin-like growth factor receptor and resistance to DACH1［J］.Cell Cycle，2011，10（12）：1956-1959．［20］ Lee MY，Moon JS，Park SW，et al. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells［J］.Biochem J，2009，417（1）：313-322.（2015-02-04收稿 2015-04-05修回）
